AS1810722
AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research[1].
Product Specifications
CAS Number
[909561-15-5]
UNSPSC
12352005
Target
Cytochrome P450; STAT
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Metabolic Enzyme/Protease; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/as1810722.html
Purity
98.10
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(N)CN1CCN(C2=CC=C(NC3=NC=C4C(N(CC5=CC(F)=CC(F)=C5)C=C4)=N3)C=C2)CC1
Molecular Formula
C25H25F2N7O
Molecular Weight
477.51
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CYP3; STAT6
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
PNLIPRP2 (Pancreatic Lipase-related Protein 2, PL-RP2, Galactolipase, PLRP2) (HRP)
Assurance Grade Titanium for AA and ICP 1000 ug/mL (1000 PPM) 250mL in H2O / 0.24 F